AbbVie Inc. (NYSE: ABBV) agreed to acquire ImmunoGen Inc. (Nasdaq: IMGN) for $10.1 billion in a move aimed at gaining access to some of the hottest new drugs in the cancer market.
To read the entire story, you must be logged in.
Please log in now or register with us.
